Control of Coronary Blood Flow During Exercise

Department of Physiology and Biophysics, University of Washington, Seattle, WA 98195-7920, USA.
Exercise and sport sciences reviews (Impact Factor: 4.26). 08/2011; 40(1):37-42. DOI: 10.1097/JES.0b013e3182348cdd
Source: PubMed


GORMAN, M. W. and E.O. FEIGL. Control of coronary blood flow during exercise. Exerc. Sport Sci. Rev., Vol. 40, No. 1, pp. 37-42, 2012. During exercise, coronary blood flow increases to match the augmented myocardial oxygen demand because of tachycardia. Coronary vasodilation during exercise is via a combination of feedforward and feedback control mechanisms. Feedforward control is mediated by sympathetic beta-adrenoceptor vasodilation. Feedback vasodilator control is via a novel hypothesis where adenine nucleotides released from red blood cells act on endothelial purinergic receptors.

Full-text preview

Available from:
  • Source
    • "The pivotal role of coronary and muscle blood flow in exercise tolerance in humans is well documented. However, the mechanisms controlling coronary and skeletal muscle blood flow during exercise involving NO, prostacyclin and ATP are not fully understood, but there is a growing body of evidence that multiple endothelial-dependent vasodilator mechanisms compensating each other are involved with erythrocyte-released ATP playing a prominent role in exercise-induced hyperaemia [49] [54] [58] [79] [117]. It is now also clear that moderate-intensity physical training affords vasoprotective, cardioprotective and neuroprotective effects involving endothelium-dependent mechanisms [136] [142] [143] that could be hindered in patients with impaired endothelial function. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this review, we present the relation between power generation capabilities and pulmonary oxygen uptake during incremental cycling exercise in humans and the effect of exercise intensity on the oxygen cost of work. We also discuss the importance of oxygen delivery to the working muscles as a factor determining maximal oxygen uptake in humans. Subsequently, we outline the importance of coronary blood flow, myocardial oxygen uptake and myocardial metabolic stability for exercise tolerance. Finally, we describe mechanisms of endothelium-dependent regulation of coronary and skeletal muscle blood flow, dysregulation of which may impair exercise capacity and increase the cardiovascular risk of exercise. Copyright © 2015 Institute of Pharmacology, Polish Academy of Sciences. All rights reserved.
    Pharmacological reports: PR 06/2015; 67(4). DOI:10.1016/j.pharep.2015.06.002 · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Das mit Abstand am häufigsten verwendete „Pharmakon“ in Anästhesie und Intensivmedizin ist medizinischer Sauerstoff (O2): Jeder Patient wird im Rahmen eines chirurgischen Eingriffs oder während eines Aufenthalts auf der Intensivstation mit O2 behandelt. In der Gebrauchsinformation von medizinischem O2 werden Hypoxie bzw. Hypoxämie unterschiedlichster Pathogenese als Indikation zur Applikation von O2 angeführt: Ziel ist die Steigerung entweder des arteriellen Sauerstoffpartialdrucks (paO2) als Therapie einer Hypoxie oder des arteriellen Sauerstoffgehalts (CaO2) als Therapie einer Hypoxämie. Die meisten klinischen Indikationen für die Gabe von O2 haben sich historisch entwickelt und wurden für lange Zeit nur wenig hinterfragt, da für die kurzfristige Anwendung von O2 das relevante Nebenwirkungsspektrum meistens als unwesentlich betrachtet wurde. Dementsprechend existieren auch nur für sehr wenige Bereiche randomisierte kontrollierte Studien, die nach Maßstäben der evidenzbasierten Medizin den Nutzen supraphysiologischer Konzentrationen von O2 beweisen. Seit Längerem ist bekannt, dass spezifische Einflüsse von O2 auf die Mikrozirkulation dessen Wirksamkeit im Hinblick auf die Gewebeoxygenierung in bestimmten Situationen sogar erheblich verringern können. So führt O2 zu einer arteriolären Konstriktion, die bei einer Vielzahl von Erkrankungen mit einer Einschränkung des regionalen O2-Angebots und hierbei mit einer Verschlechterung der Gewebeoxygenierung vergesellschaftet ist. Der vorliegende Beitrag hat zum Ziel, vor diesem Hintergrund den Stellenwert von O2 als Medikament in der klinischen Medizin kritisch zu bewerten. Oxygen (O2) is the most frequently used pharmaceutical in anesthesiology and intensive care medicine: Every patient receives O2 during surgery or during a stay in the intensive care unit. Hypoxia and hypoxemia of various origins are the most typical indications which are mentioned in the prescribing information of O2: the goal of the administration of O2 is either an increase of arterial O2 partial pressure in order to treat hypoxia, or an increase of arterial O2 content in order to treat hypoxemia. Most of the indications for O2 administration were developed in former times and have seldom been questioned from that time on as the short-term side-effects of O2 are usually considered to be of minor importance. As a consequence only a small number of controlled randomized studies exist, which can demonstrate the efficacy of O2 in terms of evidence-based medicine. However, there is an emerging body of evidence that specific side-effects of O2 result in a deterioration of the microcirculation. The administration of O2 induces arteriolar constriction which will initiate a decline of regional O2 delivery and subsequently a decline of tissue oxygenation. The aim of the manuscript presented is to discuss the significance of O2 as a pharmaceutical in the clinical setting. SchlüsselwörterSauerstoffinhalationstherapie–Partialdruck–Hyperoxie–Oxidativer Stress–Mikrozirkulation KeywordsOxygen inhalation therapy–Partial pressure–Hyperoxia–Oxidative stress–Microcirculation
    Der Anaesthesist 04/2011; 60(4):292-302. DOI:10.1007/s00101-011-1888-x · 0.76 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Coronary microvascular function is markedly impaired by the onset of the metabolic syndrome and may be an important contributor to the increased cardiovascular events associated with this mutlifactorial disorder. Despite increasing appreciation for the role of coronary K+ channels in regulation of coronary microvascular function, the contribution of K+ channels to the deleterious influence of metabolic syndrome has not been determined. Accordingly, the overall goal of this investigation was to delineate the mechanistic contribution of K+ channels to coronary microvascular dysfunction in metabolic syndrome. Experiments were performed on Ossabaw miniature swine fed a normal maintenance diet or an excess calorie atherogenic diet that induces the classical clinical features of metabolic syndrome including obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, hyperleptinemia, and atherosclerosis. Experiments involved in vivo studies of coronary blood flow in open-chest anesthetized swine as well as conscious, chronically instrumented swine and in vitro studies in isolated coronary arteries, arterioles, and vascular smooth muscle cells. We found that coronary microvascular dysfunction in the metabolic syndrome significantly impairs coronary vasodilation in response to metabolic as well as ischemic stimuli. This impairment was directly related to decreased membrane trafficking and functional expression of BKCa channels in vascular smooth muscle cells that was accompanied by augmented L-type Ca2+ channel activity and increased intracellular Ca2+ concentration. In addition, we discovered that impairment of coronary vasodilation in the metabolic syndrome is mediated by reductions in the functional contribution of voltage-dependent K+ channels to the dilator response. Taken together, findings from this investigation demonstrate that the metabolic syndrome markedly attenuates coronary microvascular function via the diminished contribution of K+ channels to the overall control of coronary blood flow. Our data implicate impaired functional expression of coronary K+ channels as a critical mechanism underlying the increased incidence of cardiac arrhythmias, infarction and sudden cardiac death in obese patients with the metabolic syndrome.
Show more